Equities

ScandiDos AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

ScandiDos AB

Actions
  • Price (SEK)1.03
  • Today's Change-0.025 / -2.38%
  • Shares traded19.65k
  • 1 Year change-29.31%
  • Beta0.3792
Data delayed at least 15 minutes, as of Feb 06 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

ScandiDos AB is a Sweden-based company active within the medical equipment sector. The Company's competence includes the design and development of radiation detectors, electrometers and application software, as well as clinical experience in medical physics and radiation measurements. The Company's business focuses on developing such applications as Arc Therapy - IMAT/VMAT, Tomotherapy, IMRT and Machine QA, among others. ScandiDos AB markets its products under the Delta4 brand. Delta4 offers Delta4AT - At Treatment in-vivo dosimetry for advanced RT and Delta4PT - Pre Treatment volumetric plan QA, among others. It operates in Europe, Asia, North America and Asia, and through numerous distributors and subsidiaries, including Additec GmbH and Conmedica GmbH in Germany, and ScandiDos SAS in France.

  • Revenue in SEK (TTM)59.37m
  • Net income in SEK-1.38m
  • Incorporated2001
  • Employees25.00
  • Location
    ScandiDos ABDag Hammarskjolds Vag 52 AUPPSALA 752 37SwedenSWE
  • Phone+46 184723030
  • Fax+46 18107402
  • Websitehttps://scandidos.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Qlife Holding AB290.00k-6.28m32.14m5.00------110.84-0.4088-3.030.0351-0.3360.0235.0930.53290,000.00-49.72-61.64-103.82-89.60-4,222.41-36.54-2,166.55-444.400.5089--2.61---79.51--76.60------
Codelab Capital AS-92.34bn-92.34bn33.64m28.00--1.12----------2.25-----------10.24---11.34--83.77---64.81----0.00---99.58-70.67-602.25---22.77--
Perpetua Medical AB (publ)13.57m3.96m34.23m11.004.574.586.322.520.87540.87543.000.87310.404613.043.874,522,697.0011.65-71.5519.36-91.644.34-49.0828.80-180.672.288.720.4216---30.1626.0486.47---32.00--
Miris Holding AB (publ)19.52m-3.93m42.50m9.00--1.97--2.18-8.82-8.8234.3416.180.70331.004.791,952,100.00-14.15-49.33-20.65-97.4785.0390.68-20.12-74.982.20-3.020.00--13.568.3553.96--8.55--
SpectraCure AB (publ)1.42m-53.17m54.31m13.00--0.3906--38.19-0.165-0.1650.00520.24680.012--1.90109,384.60-44.68-13.14-49.10-14.07835.02243.69-3,739.03-592.49---197.290.0325---46.15-13.97-12.54--0.1962--
ScandiDos AB59.37m-1.38m59.86m25.00--1.3997.021.01-0.0242-0.02421.040.75760.84161.525.602,283,539.00-1.96-8.71-3.04-14.6848.3052.29-2.33-10.670.7927--0.00--2.341.55102.23---11.62--
Neola Medical AB0.00-10.99m62.36m8.00--0.7948-----0.1479-0.14790.001.010.00----0.00-13.81-15.62-14.65-16.86--5,384.30---6,523.935.61--0.00-------11.70--35.63--
Kontigo Care AB29.11m-1.42m62.92m10.00--1.2214.772.16-0.0413-0.04130.83851.470.4809--6.65---2.340.8485-2.941.22134.25127.55-4.871.16----0.0327--4.4511.41265.57--26.69--
Redsense Medical AB (publ)30.67m302.00k64.63m4.00196.211.80109.352.110.020.021.862.180.76971.966.616,134,600.000.7578-14.280.8514-15.8661.4568.850.9846-32.794.69--0.00--12.8516.26107.58---53.01--
Luxbright AB11.06m-18.40m66.12m12.00--1.80--5.98-0.1565-0.15650.09210.28190.26857.752.83921,600.80-44.68-55.92-55.46-64.088.23-192.83-166.39-803.162.71--0.1223--955.6066.5730.18------
Scandinavian ChemoTech AB11.68m-8.70m75.71m1.00--13.16--6.48-0.3727-0.37270.50030.26530.7270.59172.661,946,333.00-54.15-92.70-83.07-131.4682.15104.65-74.49-866.060.861-5.610.00--132.6763.8534.96---59.68--
Iconovo AB1.59m-41.23m82.28m19.00--0.4465--51.85-1.67-1.670.05372.460.0117--0.260863,475.20-30.39-28.39-33.14-31.51901.69159.24-2,598.41-295.86---138.020.0391---58.55-24.2210.36--22.28--
Observe Medical ASA15.47m-114.04m82.35m4.00--3.43--5.32-26.57-26.573.290.19090.11182.878.293,350,800.00-82.38-42.22-205.00-64.146.2430.17-737.14-327.970.1175-3.720.9572---33.85153.47-98.73---2.97--
Episurf Medical AB15.60m-62.70m87.94m26.00--0.8219--5.64-0.064-0.0640.01570.06450.1641--3.95577,777.80-65.44-45.67-74.89-50.07-----398.72-857.082.50--0.0844--23.5819.3919.83--6.68--
Data as of Feb 06 2026. Currency figures normalised to ScandiDos AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
FCG Fonder ABas of 31 Mar 20257.28k0.01%
Evli Fund Management Co. Ltd.as of 30 Aug 20243.18k0.01%
Data from 30 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.